The US FDA has declined to approve the investigational antifungal olorofim, requesting more data from F2G Ltd. Despite the critical need for new antifungals due to increasing resistance, the FDA's decision highlights the challenges in drug development for rare fungal diseases. Olorofim, a breakthrough therapy, shows promise in treating invasive mold infections, but faces hurdles in gaining approval. Physicians have witnessed success with olorofim under compassionate use programs, emphasizing its potential. However, concerns about safety, efficacy, and cost remain, reflecting the complexities of antifungal drug development. The FDA's complete response letter to F2G signals the need for further discussions on olorofim's potential benefits and risks. The global threat of fungal infections underscores the urgency for innovative antifungal treatments, despite existing challenges in drug approval processes.
In eine andere Sprache
aus dem Quellinhalt
www.medscape.com
Wichtige Erkenntnisse aus
by Marcia Frell... um www.medscape.com 06-21-2023
https://www.medscape.com/viewarticle/993520Tiefere Fragen